Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Comparisons
Put two evidence files side by side.
Each comparison names a default winner, explains the reason, and states the conditions that can change the verdict.
BPC-157: 70+ rodent studies, single research group, no human efficacy data.
TB-500 won the only direct 2026 head-to-head animal study, but neither peptide has established human healing efficacy and the combination added no benefit.
Research distinction: When sustained IGF-1 elevation is the research goal and the non-pulsatile GH profile is acceptable vs. ipamorelin goals.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Selank: Russian RCT evidence (Semenova 2010, n=38) showing improved declarative memory and anxiolytic effects; approved in Russia.
Semax: Russian multicenter RCT data in ischemic stroke (Lebedeva 2008, n=60), approved in Russia and Ukraine.
Research distinction: epithalon goals vs. Skin rejuvenation, wound healing, or collagen synthesis research where human efficacy data matters.
Elamipretide has accelerated FDA approval for a narrow Barth-syndrome population; epithalon has no independent or regulatory evidence of comparable quality.
GHK-Cu has the stronger evidence when human evidence matters; TB-500 fragment 17-23 remains preclinical.
Research distinction: ipamorelin goals vs. sermorelin goals.
PT-141/bremelanotide: FDA approved (Vyleesi) for HSDD in premenopausal women 2019 - multiple Phase 2/3 RCTs.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: Lower-cost alternative when formulary access drives choice, or when a less potent GLP-1 agent with d vs. tirzepatide goals.
LL-37 has the stronger human biology evidence; direct TB-500 fragment evidence remains preclinical.
Tirzepatide is the stronger research reference for weight-loss magnitude; semaglutide is the stronger research reference when mature GLP-1-only cardiovascular outcomes evidence is the priority.
Research distinction: Anxiety, stress, and mood-related cognitive impairment research vs. Stroke recovery, neuroprotection, or cognitive performance enhancement research focused on BDNF mech.
5-Amino-1MQ: mouse-only data from a single research group targeting NNMT inhibition; no human trials.
Research distinction: NNMT inhibition and NAD+ metabolism research in preclinical models vs. Research requiring human safety data or GH-fragment lipolysis mechanisms, with the caveat that Phase.
Research distinction: NNMT-specific metabolic research or NAD+ pathway studies vs. Mitochondrial biology, AMPK signaling, or exercise-mimetic research where MOTS-c has broader indepen.
Tesofensine: Phase 2b RCT (Astrup et al.
Abarelix: FDA approved 2003 for advanced prostate cancer, withdrawn from US market due to 3.7% immediate-onset systemic allergic reaction rate.
Degarelix: FDA approved 2008 (Firmagon) for advanced prostate cancer, Phase 3 (CS21, Van Poppel et al.
Gonadorelin: FDA approved for diagnostic evaluation of gonadotropic function, well-characterized as the endogenous GnRH decapeptide.
Leuprolide: FDA approved since 1985, used in prostate cancer, endometriosis, precocious puberty, and IVF - extensive Phase 3 and post-marketing data spanning 40+ years.
Triptorelin: FDA approved (Trelstar) for advanced prostate cancer, with Phase 3 data and broad international use including gender-affirming care.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Ac-SDKP has the broader independent evidence base; TB-500 fragment evidence is limited to preclinical repair studies.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Liraglutide: FDA approved (Saxenda) for obesity, SCALE trial (Pi-Sunyer et al.
Semaglutide: FDA approved (Wegovy/Ozempic), STEP-1 trial (Wilding et al.
Tesofensine: Phase 2b RCT (Astrup et al.
Pramlintide has the stronger current evidence today when approved amylin-specific human evidence matters; amycretin/zenagamtide is the stronger future-watch obesity program.
Semaglutide is the stronger research reference today because it is approved and outcomes-rich; amycretin/zenagamtide is an important Phase 3 pipeline challenger.
Tirzepatide is the stronger research reference today because it is approved and has mature Phase 3 obesity data; amycretin/zenagamtide is still a pipeline challenger.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
TB-500 has direct animal evidence; AOD-14 has no identifiable peer-reviewed evidence.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Ipamorelin: Phase 2 data from Helsinn for post-operative ileus, with selective GH secretagogue effects.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: GH fragment lipolysis research independent of GH axis stimulation vs. GH deficiency or GH stimulation research where FDA-reviewed human data and pulsatile GH release are .
Tesamorelin: FDA approved 2010 (Egrifta) for HIV-associated lipodystrophy, with Phase 3 RCTs showing significant visceral fat reduction (Falutz et al.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Bivalirudin: direct thrombin inhibitor, HORIZONS-AMI (n=3,602) showing reduced bleeding vs.
Bivalirudin: FDA approved, HORIZONS-AMI demonstrated clinically meaningful bleeding reduction in PCI - maintains active clinical use.
Research distinction: Anticoagulation during percutaneous coronary intervention vs. Vasodilatory shock, cardiac arrest (ACLS protocol), or diabetes insipidus treatment.
Bortezomib: FDA approved 2003 (Velcade), VISTA trial and multiple Phase 3 RCTs establishing it as backbone of myeloma therapy.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Chrysalin (TP508): Phase 2 human trial data for diabetic foot ulcers and bone fracture repair (Stiernberg et al.) showing acceleration of wound healing.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Glutathione: endogenous tripeptide antioxidant with extensive human pharmacological, supplementation, and clinical data across dermatology, hepatology, and toxicology.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: ADNF/humanin-pathway neuroprotection research in rodent models vs. Aging-related cognitive decline research where primate data adds translational credibility.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: Basic research into copper-peptide mechanisms at the cellular level vs. Cosmetic formulation research where some independent collagen-stimulation data is available.
Research distinction: Research into copper-delivery peptide mechanisms at the cellular level vs. TGF-beta-pathway collagen stimulation research with manufacturer-level formulation data available.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Cortexin: approved in Russia, Russian clinical data for neuroprotection.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: Broad neuroprotection contexts within Russian clinical practice vs. Stroke recovery or BDNF-mediated neuroprotection research requiring a defined molecule with multicen.
Research distinction: Neurological research within the Russian peptide bioregulator framework vs. Immunomodulation or thymic reconstitution research, particularly age-related immune decline.
Daptomycin (Cubicin): FDA approved for complicated skin infections and S.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both: FDA approved.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: Sleep architecture research with access to historical human EEG data from DSIP studies vs. Pineal gland biology research within the Khavinson peptide bioregulator framework.
Goal-dependent: DSIP for sleep/circadian research, thymalin for immune-thymic aging research - different target organs with no meaningful overlap.
Research distinction: Sleep neurophysiology research where historical human EEG data exists vs. Khavinson dipeptide bioregulator research focused on immune modulation, accepting extremely limited .
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: T2DM requiring GLP-1 agonist therapy with CV risk reduction evidence vs. Prandial glucose excursion control, particularly in T1DM where GLP-1 agonists are not indicated - pr.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Liraglutide: LEADER trial (n=9,340, HR 0.87 for MACE, p=0.01) demonstrated cardiovascular benefit.
Exenatide: FDA approved (Byetta 2005, Bydureon 2012), multiple Phase 3 RCTs, EXSCEL CVOT.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Semaglutide: SUSTAIN and STEP Phase 3 programs, SELECT CVOT (HR 0.80 for MACE), ~15% weight loss.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Tirzepatide: SURMOUNT Phase 3 (22.5% weight loss), SURPASS Phase 3 for T2DM, FDA approved (Mounjaro/Zepbound).
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: Senescence-focused aging research using the Baar 2017 paradigm vs. Immune aging (immunosenescence) research where thymic restoration is the target, accepting Khavinson.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
GHK-Cu: Level B, positive small human RCTs for skin.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Elamipretide has accelerated FDA approval for Barth syndrome; choose GHK-Cu only for skin and matrix-remodeling questions.
TB-500 has the clearer direct preclinical repair study; neither compound has decision-grade human efficacy evidence.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: Pure GH secretagogue research where CD36 cardiovascular confounding is undesirable vs. Cardiovascular research exploring CD36-mediated cardioprotection alongside GH release.
GHRP-2: stronger GH release per dose in comparative studies.
Macimorelin: FDA approved (2017) for adult GH deficiency diagnosis, Phase 3 validation trial vs.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Ipamorelin: Phase 2 post-operative ileus trial (Helsinn), demonstrated hormonal selectivity.
Macimorelin: FDA approved (2017) diagnostic GH secretagogue, Phase 3 validation.
MK-677: oral, Merck Phase 3 datasets in elderly (Nass 2008), 24-hour half-life.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Thymosin alpha-1 (thymalfasin): approved in 35+ countries, human RCTs for HBV (Chien 1998) and HCV, Phase 3 data in hepatitis.
Gonadorelin: FDA approved for diagnostic use and clinical GnRH replacement, decades of human data.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both FDA approved.
Ipamorelin: Phase 2 post-operative ileus data, demonstrated selectivity - no cortisol/prolactin effects.
MK-677: oral, Merck Phase 3 datasets (Nass 2008, elderly), 24-hour half-life.
Sermorelin: FDA approved (withdrawn commercially 2008), adult RCT data (Walker 1997), GHRH mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Elamipretide has accelerated FDA approval for Barth syndrome; humanin remains preclinical.
Research distinction: Repeated-dose GH secretagogue research requiring hormonal selectivity and no cortisol/prolactin conf vs. GH deficiency diagnosis with an FDA-approved oral reference standard.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Pegvisomant (Somavert): FDA approved (2003) GH receptor antagonist for acromegaly, Phase 3 data (Trainer 2000, NEJM), well-characterized in thousands of patients.
Tesamorelin: FDA approved (2010) for HIV-associated lipodystrophy, Phase 3 data showing visceral fat reduction (Falutz 2007, 2008).
Leuprolide (Lupron): FDA approved, one of the most widely used GnRH agonists worldwide, extensive Phase 3 data across prostate cancer, endometriosis, precocious puberty, and IVF.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
NAD+ (via NR/NMN): multiple human RCTs showing NAD+ level increases (Martens et al.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Nesiritide (Natrecor): ASCEND-HF (n=7,141) showed no benefit on dyspnea or mortality vs.
Vasopressin (ADH): established role as second-line vasopressor in septic shock (VASST trial, Russell 2008, n=778) and cardiac arrest (AHA guidelines).
Vancomycin: decades of clinical use, thousands of clinical trials, guideline-directed therapy for MRSA and C.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Octreotide: US guideline-directed therapy for variceal bleeding, decades of clinical data.
Octreotide: decades of data across acromegaly, carcinoid, and variceal bleeding.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
P15-peptide: FDA 510(k) clearance as a bone graft substitute (collagen-binding synthetic peptide, PepGen P-15), clinical data in dental and orthopedic bone regeneration.
Pegvisomant (Somavert): FDA approved for acromegaly, Phase 3 data showing IGF-1 normalization in ~90% of patients (Trainer et al.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Pramlintide: FDA approved for T1DM and T2DM as adjunct to insulin, published Phase 3 data showing HbA1c reduction and modest weight loss.
Semaglutide: FDA approved, STEP trials (14.9% mean weight loss), SELECT CVOT (HR 0.80 for MACE, n=17,604).
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Research distinction: CNS-focused bioregulator research within the Khavinson framework only vs. Immune/thymic-focused bioregulator research within the Khavinson framework only.
Semaglutide: STEP trials (14.9% weight loss), SELECT CVOT (HR 0.80 MACE).
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Semaglutide: STEP-1 (14.9% weight loss), SELECT CVOT (HR 0.80, n=17,604).
Both peptides serve distinct research goals with comparable evidence; choose by target mechanism.
Retatrutide is the stronger research reference for obesity magnitude because its Phase 3 topline weight-loss signal is substantially larger; choose survodutide when liver/MASH biology is the central question.